Equillium, Inc. (NASDAQ:EQ) Short Interest Up 666.5% in August

Key Points

• Equillium, Inc. experienced a massive increase in short interest of 666.5% in August, rising from 427,900 shares to a total of 3,280,000 shares.
• The company's stock price declined by 10.1% recently, trading at $1.57, with a twelve-month low of $0.27 and a high of $2.26.
• Equillium reported a quarterly loss of ($0.16) earnings per share, missing the consensus estimate by $0.02, and has a negative return on equity of 139.56%.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) was the recipient of a large increase in short interest during the month of August. As of August 15th, there was short interest totaling 3,280,000 shares, anincreaseof666.5% from the July 31st total of 427,900 shares. Based on an average daily volume of 7,930,000 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 7,930,000 shares, the days-to-cover ratio is currently 0.4 days.

Equillium Stock Down 10.1%

EQ stock traded down $0.18 during midday trading on Tuesday, hitting $1.57. 388,280 shares of the company traded hands, compared to its average volume of 3,454,677. Equillium has a twelve month low of $0.27 and a twelve month high of $2.26. The stock has a market capitalization of $93.12 million, a price-to-earnings ratio of -2.79 and a beta of 1.54. The business has a 50 day simple moving average of $0.74 and a 200-day simple moving average of $0.60.

Equillium (NASDAQ:EQ - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equillium had a negative return on equity of 139.56% and a negative net margin of 19.62%. Equities research analysts forecast that Equillium will post 0.14 EPS for the current year.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.